 |
|
|
Methylphenobarbital
|
|
| Systematic (IUPAC) name | |
| 5-phenyl-5-ethyl- 3-methylbarbituric acid |
|
| Identifiers | |
| CAS number | 115-38-8 |
| ATC code | N03AA01 |
| PubChem | 8271 |
| DrugBank | APRD00047 |
| Chemical data | |
| Formula | C13H14N2O3 |
| Mol. mass | 246.3 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 70-76% |
| Metabolism | Hepatic |
| Half life | 34 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ?
|
Methylphenobarbital, also known as mephobarbital, (marketed in the US under the brand name Mebaral by Ovation) is a drug which is a barbiturate derivative.
Methylphenobarbital is used as a sedative, anxiolytic and anticonvulsant. It is the N-methylated analogue of phenobarbital, and has similar indications, therapeutic value, and tolerability.
Approval History
- 1935 Mebaral was introduced by Winthrop Pharmaceuticals.
- 2001 Methylphenobarbital discontinued in the UK.
- 2003 Mebaral acquired by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
Overdose symptoms
Symptoms of overdose of mephobarbital include confusion, decrease in or loss of reflexes, somnolence, pyrexia, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness
References
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
|
|||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
